A practical reference on post-marketing surveillance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Traceability: The ability to reconstruct the development history of a drug or medical device. Accountability: The ability to resolve who has contributed what to the development and when. Another version, ALCOA++, adds:
Because of the large energy distribution, ions with similar mass/charge ratio can have very different kinetic energies and will thus experience different deflection for the same magnetic field. In practical terms one would see that ions with the same mass/charge ratio focus at different points in space. However, in a mass-spectrometer one wants ions with the same mass/charge ratio to focus at the same point, e.g. where the detector is located. In order to overcome these limitations, commercial MC-ICP-MS are double-focusing instruments. In a double-focusing mass-spectrometer ions are focused due to kinetic energy by the ESA (electro-static-analyzer) and kinetic energy + mass/charge (momentum) in the magnetic field. Magnet and ESA are carefully chosen to match the energy focusing properties of one another and are arranged so that the direction of energy focusing is in opposite directions. To simplify, two components have an energy focus term, when arranged properly, the energy term cancels out and ions with the same mass/charge ratio focus at the same point in space. Double-focusing does not reduce the kinetic energy distribution and different kinetic energies are not filtered or homogenized. Double-focusing works for single as well as multi-collector instruments. In single collector instruments ESA and magnet can be arranged in either forward geometry (first ESA then magnet) or reversed geometry (magnet first then ESA), as only point-to-point focusing is required.
== Adverse effects == More serious side effects of Mobocertinib may include agitation, bloating of the eyes, lips, feet, blurred vision, coma, decreased urine output, headache, hostility, diarrhea, depression, dizziness, fainting, lethargy, anxiety, nausea, seizures, weight gain, fatigue as well as edema. Other side effects which may be less frequent are: chills, cough, dilated neck veins, ill-feeling and trouble with breathing. Other notable side effects of taking Mobocertinib are: having an acidic stomach, heartburn, acidity, hair loss/thinning, bone pain, sore throat, stuffy nose, trouble swallowing, vomiting and weakness in hands and feet.
Sources: en.wikipedia.org
=== July === 1 July Ofgem lowers the energy price cap, saving the average household £122 a year on gas and electric. Passenger and crew of British Airways Flight 149, which was seized by Iraqi authorities when it landed at Kuwait International Airport in August 1990 at the start of the Gulf crisis, are to sue British Airways and the UK government for "deliberately endangering" them after they were held hostage by Iraq. For the second time in three months, military horses break free and run loose through central London. Euro 2024: UEFA investigate Jude Bellingham for a gesture he made following his late equaliser against Slovakia in England's victory in the last-16 tie. Bellingham says it was an inside joke directed at close friends. 2 July Three-time tennis champion Andy Murray, 37, withdraws from the Wimbledon singles, following recent surgery on his back. He will attempt to compete in the doubles, which are likely to mark his final appearance in the tournament prior to retiring later in the year. Following her conviction in August 2023, former neonatal nurse Lucy Letby is found guilty in a separate retrial of attempting to murder a premature child, referred to in court as Baby K. St James's University Hospital nursing assistant Mohammad Farooq is convicted at Sheffield Crown Court of crimes relating to plotting lone wolf attacks on RAF Menwith Hill in North Yorkshire and his Leeds workplace. Data obtained by BBC News shows that 1.8 million people owe at least £50,000 in student debt.
Nandrolone, also known as 19-nortestosterone, is an endogenous androgen. It is also an anabolic steroid (AAS) which is medically used in the form of esters such as nandrolone decanoate (brand name Deca-Durabolin) and nandrolone phenylpropionate (brand name Durabolin). Nandrolone esters are used in the treatment of anemias, cachexia (muscle wasting syndrome), osteoporosis, breast cancer, and for other indications. They are now used by oral administration or instead are given by injection into muscle or fat. Side effects of nandrolone esters include symptoms of masculinization like acne, increased hair growth, and voice changes. They are synthetic androgens and anabolic steroids and hence are agonists of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). Nandrolone has strong anabolic effects and weak androgenic effects, which give them a mild side effect profile and make them especially suitable for use in women and children. There are metabolites of Nandrolone that act as long-lasting prodrugs in the body, such as 5α-Dihydronandrolone. Nandrolone esters were first described and introduced for medical use in the late 1950s. They are among the most widely used anabolic steroid worldwide. In addition to their medical use, nandrolone esters are used to improve physique and performance, and are said to be the most widely used anabolic steroid for such purposes. The drugs are controlled substances in many countries and so non-medical use is generally illicit.
Club, described the film as "boneheaded" and "a perfect hate-watch" noting that Macdonald "slaps together some cheap, quick-cut montages gesturing at the modern surveillance state" but lacks the "feel for the pace or tension needed to keep the energy up in a film like this," and commenting that "The extended workout, either shot so far away that it looks like stock footage or so tight that it loses all sense of context, is never any more exciting than watching Gadot lope on a treadmill." Dennis Harvey, in a similarly negative review for Variety, wrote that the film "lacks the strong suspense or novelty necessary to elevate an overfamiliar concept" and criticized the acting, saying "Nor is Gadot a performer inclined to lend much more than athleticism to a role that could use some warmth and idiosyncrasy to color its rather generic action-hero gist." In a review for TheWrap, William Bibbiani wrote, "The Runner isn't much of a thriller. It isn't much of a movie. It would, however, be a hilarious episode of Taskmaster."
=== Other wins (11) === 1955 Egyptian Matchplay 1965 World Series of Golf, NTL Challenge Cup (Canada), World Cup of Golf, World Cup of Golf Individual Trophy 1968 World Series of Golf 1972 World Series of Golf 1977 World Cup of Golf Individual Trophy 1979 PGA Grand Slam of Golf (shared title with Andy North) 1983 Skins Game 1986 Fred Meyer Challenge (with Greg Norman - team shared title with Peter Jacobsen and Curtis Strange)
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.